EW 📈 Edwards Lifesciences - Overview

Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US28176E1082

EW: Heart Valves, Surgical Systems, Monitoring Systems

Edwards Lifesciences Corporation is a leading medical technology company that develops and manufactures innovative products and technologies for structural heart disease and critical care monitoring. With a strong presence in the United States, Europe, Japan, and other international markets, the company is dedicated to improving patient outcomes and enhancing the quality of life for people around the world.

The company's product portfolio includes a range of transcatheter heart valve replacement and repair solutions, such as the Edwards SAPIEN family of valves system, PASCAL PRECISION, and Cardioband, which enable minimally invasive procedures for aortic, mitral, and tricuspid valve diseases. These cutting-edge technologies have revolutionized the treatment of structural heart disease, offering patients less invasive and more effective treatment options.

In addition to its transcatheter solutions, Edwards Lifesciences also provides surgical structural heart solutions, including aortic surgical valves, such as the INSPIRIS and INSPIRIS RESILLA valves, which feature advanced RESILIA tissue and VFit technology. The company's KONECT RESILIA pre-assembled tissue valves conduit and MITRIS RESILIA valve are designed for complex combined procedures, offering surgeons and patients a range of options for treating structural heart disease.

Edwards Lifesciences is also a leader in critical care monitoring, offering a suite of hemodynamic monitoring systems, including FloTrac, Acumen IQ sensors, ClearSight, Acumen IQ cuffs, and ForeSight, which enable clinicians to accurately measure a patient's heart function and fluid status in surgical and intensive care settings. The company's HemoSphere monitoring platform and Acumen Hypotension Prediction Index software provide real-time physiological information, empowering clinicians to make informed decisions and improve patient outcomes.

The company's products are distributed through a direct sales force and independent distributors, ensuring that its innovative solutions reach patients and healthcare providers around the world. With a rich history dating back to 1958, Edwards Lifesciences Corporation is headquartered in Irvine, California, and continues to drive innovation and advancements in the medical technology industry.

Additional Sources for EW Stock

EW Stock Overview

Market Cap in USD 42,082m
Sector Healthcare
Industry Medical Devices
GiC Industry Health Care Equipment & Supplies
TER 0.00%
IPO / Inception 2000-03-27

EW Stock Ratings

Growth 5y -20.8%
Fundamental 38.9%
Dividend -
Rel. Performance Sector -0.85
Analysts 3.66/5
Fair Price Momentum 62.90 USD
Fair Price DCF 20.50 USD

EW Dividends

Dividend Yield 12m 0.00%
Yield on Cost 5y 0.00%
Annual Growth 5y 0.00%
Payout Consistency 0.00%

EW Growth Ratios

Growth Correlation 3m 42.6%
Growth Correlation 12m -48.4%
Growth Correlation 5y -11.7%
CAGR 5y -2.72%
CAGR/Mean DD 5y -0.12
Sharpe Ratio 12m 0.18
Alpha -36.61
Beta 1.16
Volatility 26.99%
Current Volume 6509.8k
Average Volume 20d 4568.2k
What is the price of EW stocks?
As of December 03, 2024, the stock is trading at USD 70.53 with a total of 6,509,833 shares traded.
Over the past week, the price has changed by -1.04%, over one month by +6.11%, over three months by +2.59% and over the past year by +1.95%.
Is Edwards Lifesciences a good stock to buy?
Partly, yes. Based on ValueRay Fundamental Analyses, Edwards Lifesciences (NYSE:EW) is currently (December 2024) ok to buy, but has to be watched. It has a ValueRay Fundamental Rating of 38.91 and therefor a somewhat positive outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of EW as of December 2024 is 62.90. This means that EW is currently overvalued and has a potential downside of -10.82%.
Is EW a buy, sell or hold?
Edwards Lifesciences has received a consensus analysts rating of 3.66. Therefor, it is recommend to hold EW.
  • Strong Buy: 8
  • Buy: 5
  • Hold: 19
  • Sell: 0
  • Strong Sell: 0
What are the forecast for EW stock price target?
According to ValueRays Forecast Model, EW Edwards Lifesciences will be worth about 70.2 in December 2025. The stock is currently trading at 70.53. This means that the stock has a potential downside of -0.44%.
Issuer Forecast Upside
Wallstreet Target Price 76.6 8.6%
Analysts Target Price 91.3 29.5%
ValueRay Target Price 70.2 -0.4%